Home|Journals|Articles by Year|Audio Abstracts
 

Review Article



The linkage between the second wave of COVID-19 and the severity of mucormycosis in India

Kshama Wamanrao Murarkar, Shilpa Prakash Mankar.




Abstract
Cited by 0 Articles

The whole world was fighting the danger of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) since 2019. The SARS-CoV-2 virus was mutating with great speed, and putting new challenges in front of the world. In India, the whole healthcare system was engaged in tackling the second wave of COVID-19 as a result of virus mutation. Additionally, a fungal co-infection, mucormycosis started to invade the COVID- 19 patients. Mucormycosis is an acute infection, caused by an opportunistic fungus, mostly attacks the immunosuppressed, diabetic, and neutropenia patients. The other causes of infection include inappropriate use of immunosuppressive drugs, entry of Mucorales through open wounds, cancer, acquired immune deficiency syndrome, organ transplant, and malnutrition. In the recent mucormycosis outbreak in India, all the mucormycosis cases included eyesight damage, facial deformities, and even death in critical conditions. These reported mucormycosis cases in India were mostly diabetes, which were treated with immunosuppressive drugs. The mucormycosis fungus was probably invading the recovered, or near to recovery the second wave COVID-19 patients. In this review, we discussed the important risk factors responsible for the sudden outbreak of mucormycosis, and its severity linked to second wave COVID-19 patients in India.

Key words: Keywords: Mucormycosis, COVID-19, diabetes, immunosuppression, Second wave of SARS-CoV-2






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.